Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy
Sponsored by Hospital Miguel Servet
About this trial
Last updated 4 years ago
Study ID
C1834-MADIT
Status
Completed
Type
Interventional
Phase
Phase 3
Placebo
No
Accepting
18 to 80 Years
All Sexes
Trial Timing
Ended 4 years ago
What is this trial about?
The objective of this study is to determine the effect of the sealant patch Hemopatch, compared to current practice without any sealant, on the decrease of the postoperative pancreatic fistula on patients undergoing pancreatoduodenectomy for benign or malignant tumors or other benign process.
What are the participation requirements?
Inclusion Criteria
* Patients scheduled for pancreatoduodenectomy by open approach, depending on the diagnosis/nature of the tumor.
* ASA score < 4.
* Male and female patients ≥ 18 and ≤ 80 years of age.
* With the consent form signed.
Exclusion Criteria
* Patients scheduled for pancreatoduodenectomy by open approach, depending on the diagnosis/nature of the tumor.
* ASA score < 4.
* Male and female patients ≥ 18 and ≤ 80 years of age.
* With the consent form signed.